Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00228566
Status:
COMPLETED
Last Update Posted:
2013-07-19
First Post:
2005-09-27
Brief Title:
Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep ApneaHypopnea Syndrome
Sponsor:
Cephalon
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A Short-term 8 Week Open-Label Study Followed by a Long Term Evaluation to Assess Patient-Reported Outcomes With Armodafinil Treatment 150 to 250 mgDay for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep ApneaHypopnea Syndrome
Status:
COMPLETED
Status Verified Date:
2013-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess patient reported outcomes with armodafinil treatment in terms of improvement in sleepiness satisfaction with treatment impact on ability to engage in life activities ie daily or work and family andor social activities and effects on fatigue Clinician ratings on patient response to armodafinil treatment will also be assessed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None